新股暗盤 | 雍禾醫療(2279.HK)暗盤段漲5%
格隆匯12月10日丨據富途證券,雍禾醫療(2279.HK)暗盤段現報16.6港元,較發行價15.8港元漲5%,總市值86.3億港元。公司主要提供毛髮醫療服務,2018年至2020年收益分別為9.34億、12.24億、16.38億元人民幣,淨利分別為5350萬、3562.4萬、1.63億元人民幣,每股有形資產淨值3.78港元,2020歷史市盈率40.89倍。此次市場發售9442.4萬股,其中香港發售4721.2萬股,國際發售4721.2萬股,每手500股,一手中籤率15%,香港公開發售獲160.06倍認購,淨籌13.567億港元,當中約42.1%用於為中國境內網絡的現有植髮醫療機構進行擴充和升級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.